Deutsche Bank AG Sells 80,170 Shares of Haemonetics Corporation (NYSE:HAE)

Deutsche Bank AG reduced its stake in shares of Haemonetics Corporation (NYSE:HAE) by 16.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 399,415 shares of the medical instruments supplier’s stock after selling 80,170 shares during the period. Deutsche Bank AG’s holdings in Haemonetics were worth $25,383,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Royce & Associates LP boosted its holdings in Haemonetics by 0.7% in the 1st quarter. Royce & Associates LP now owns 1,161,296 shares of the medical instruments supplier’s stock worth $73,800,000 after buying an additional 8,028 shares during the period. Boston Trust Walden Corp boosted its holdings in Haemonetics by 22.1% in the 1st quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier’s stock worth $71,070,000 after buying an additional 202,609 shares during the period. Dimensional Fund Advisors LP lifted its stake in Haemonetics by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier’s stock worth $77,470,000 after purchasing an additional 10,990 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Haemonetics by 20.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier’s stock worth $60,888,000 after purchasing an additional 165,118 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Haemonetics by 16.1% during the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier’s stock valued at $52,959,000 after purchasing an additional 93,848 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Robert W. Baird assumed coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price target for the company. Barrington Research reduced their price target on shares of Haemonetics from $95.00 to $86.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research report on Wednesday, June 25th. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Finally, Mizuho reduced their price target on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $85.18.

Haemonetics Stock Performance

NYSE HAE opened at $53.95 on Thursday. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The company has a market capitalization of $2.60 billion, a P/E ratio of 16.50, a P/E/G ratio of 0.96 and a beta of 0.40. The company has a fifty day moving average of $71.89 and a 200-day moving average of $67.04.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.09. The company had revenue of $321.39 million for the quarter, compared to analysts’ expectations of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.02 EPS. As a group, equities research analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.